PD-1 and PD-L1 Inhibitors represent critical components of the immune checkpoint system that normally prevents excessive immune responses. Under physiological conditions, this pathway serves as a regulatory mechanism to maintain immune homeostasis and prevent autoimmune reactions. However, cancer cells exploit this natural braking system by overexpressing PD-L1, effectively disguising... https://www.feedsfloor.com/market-research/pd-1-and-pd-l1-inhibitors-revolutionizing-cancer-treatment-through-advanced